Wed, Apr 3rd 2024
Geneva-based ObsEva, dedicated to pioneering women’s reproductive health solutions, announces its upcoming delisting from the SIX Swiss Exchange.
ObsEva SA, a Geneva-based biopharmaceutical innovator focusing on women’s reproductive health, has announced its delisting from the SIX Swiss Exchange, slated for May 2024.
This decision comes after obtaining approval from the Regulatory Board of the SIX Swiss Exchange, which also granted ObsEva an exemption from several listing maintenance obligations according to a press release.
The final day for trading ObsEva shares on the SIX Swiss Exchange is set for Friday, May 3, 2024, with the official delisting effective from Monday, May 6, 2024.
This move follows a directive issued by SIX Exchange Regulation, which relieves ObsEva from numerous reporting and publication requirements traditionally mandated for listed entities.
Among these exemptions are the publication and submission of the annual report for 2023, ad hoc announcements with the exception of the delisting date notice, disclosure of management transactions, maintenance of a corporate calendar, and specific regular reporting obligations.
English 
German 
French 
Spanish 
Arabic